Ignite Creation Date:
2024-05-06 @ 9:27 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02983838
Status:
UNKNOWN
Last Update Posted:
2016-12-06
First Post:
2016-04-13
Brief Title:
Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor and Amyloid Neuroimaging
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Development of Biomarker With Neuroimaging Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor BDNF and Amyloid Neuroimaging
Status:
UNKNOWN
Status Verified Date:
2016-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Target of the research Based on change of Brain-derived neurotrophic factor and other pro-inflammatory cytokine along with symptom improvement following treatment the investigators are trying to find the new treatment target molecule The investigators will follow up the subjective and objective cognitive dysfunction with psychiatric symptom profiles and compare the neuroimaging related to these change
Detailed Description:
Recently the investigators reported the association between childhood trauma and refractory depression which related to Brain Derived Neurotrophic Factor BDNF Even though level of peripheral BDNF is closely related to depression treatment the investigators still have little idea on role of BDNF In this research the investigators are going to find the genetic variation affecting treatment response and process figure out specific role of BDNF in depressive patient correlated with Neuroimaging Along with BDNF many kinds of proinflammatory cytokine showed increased amount related to depressive patient Leptin adiponectin and plasma tryptohphan are also seen to be related to response of depression Here the investigators are trying to see specific difference on neuroimaging shown in depressive patient related to peripheral marker The investigators will evaluate the 36 depressive patients compared to 24 normal control For depressive patients after excluding other bipolar spectrum disorder psychotic disorder other neurocognitive disorder subjects who have organic brain lesion tested as HAM D score above 16 will be included in this research As a psychiatric evaluation the investigators will do the MINI International Psychiatric Interview Plus MINI Plus Suicidal ideation evaluation Hamilton Depression Inventory 17 HAM D 17 Hamilton Anxiety Inventory HAM A to get the information of their clinical severity As a neuroimaging evaluation the investigators will do the magnetic resonance imaging MRI with diffusion tensor imaging and amyloid Positron Emission TomographyPET to see the specific deposition For peripheral marker for inflammation and other neurotrophic factor the investigators will do the platelet BDNF leveland other pre-inflammatory factors The investigators will also check for genotyping for BDNF For follow up evaluation the investigators will keep up the psychiatric evaluation with HAM D HAM A and peripheral proteinomic evaluation with platelet BDNF level and other pro-inflammatory cytokines
This research will figure out the correlation between neurotrophic factor as BDNF and inflammatory factor seen in peripheral blood assay with treatment response in depression Also the investigators are trying to integrate the peripheral change along with BDNF genotyping and specific change seen in neuroimaging Replicating this research with high statistical power would be promising to find reliable peripheral marker for prognosis of depression
This research will figure out the correlation between neurotrophic factor as BDNF and inflammatory factor seen in peripheral blood assay with treatment response in depression Also the investigators are trying to integrate the peripheral change along with BDNF genotyping and specific change seen in neuroimaging Replicating this research with high statistical power would be promising to find reliable peripheral marker for prognosis of depression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None